Search

Displaying results 4261 - 4270 of 10000 in total
  1. Drug

    Cloxazolam

    go.drugbank.com/drugs/DB01553
    Experimental

    The usual dose of cloxazolam in adults is 3-12mg/day for anti-anxiety. … As well, it has also been studied in Japan in doses of 15-30mg/day as an adjunct in the treatment of intractable epilepsy, for which it has demonstrated effectiveness.

    Products: OLCADIL ® 2 MG COMPRIMIDOS, OLCADIL ® 1 MG COMPRIMIDOS
  2. Drug

    Miglitol

    go.drugbank.com/drugs/DB00491
    Approved

    Miglitol should be taken at the start of a meal for maximal effect and the effect will depend on the amount of poly and oligosaccharides in the diet. … Unlike other drugs of the same class, miglitol is not metabolized and the unmetabolized drug is excreted by the kidneys.

    Products: DIASTABOL 50 MG, DIASTABOL 100 MG
  3. Drug

    Ritanserin

    go.drugbank.com/drugs/DB12693
    Investigational

    Ritanserin has been used in trials studying the treatment of Cocaine-Related Disorders.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  4. Drug

    Acarbose

    go.drugbank.com/drugs/DB00284
    ApprovedInvestigational

    Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. … [L31633,A37868] By inhibiting the activity of these enzymes, acarbose limits the absorption of dietary carbohydrates and the subsequent postprandial increase in blood glucose and insulin levels.

    Products: ACARBOSA 50 MG, ACARBOSA 100 MG
  5. Drug

    Zomepirac

    go.drugbank.com/drugs/DB04828
    ApprovedWithdrawn

    Zomepirac, formerly marketed as Zomax tablets, was associated with fatal and near-fatal anaphylactoid reactions. The manufacturer voluntarily removed Zomax tablets from the Canadian, US, and UK markets in March 1983.

  6. Drug

    Nirogacestat

    go.drugbank.com/drugs/DB12005
    ApprovedInvestigational

    and thus impede the growth of desmoid tumors. … [A262561] Nirogacestat was approved under the brand name OGSIVEO on November 27, 2023, by the FDA for the treatment of adult patients with progressing desmoid tumors who require systemic treatment.

  7. Drug

    Bleomycin

    go.drugbank.com/drugs/DB00290
    ApprovedInvestigational

    A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0).

    Products: BLEOCIN 15 MG LIYOFILIZE AMPUL, 1 ADET, BLEMISIN 15 MG LIYOFILIZE TOZ ICEREN FLAKON, 1 ADET
  8. Drug

    Ibudilast

    go.drugbank.com/drugs/DB05266
    Investigational

    (codes: AV-411 or MN-166), but is approved for use as an antiinflammatory in Japan. … shrinkage in patients with relapsing-remitting (RR) and/or secondary progressive (SP) multiple sclerosis (MS).

  9. Drug

    Dirucotide

    go.drugbank.com/drugs/DB04921
    Investigational

    Dirucotide has been developed for the treatment of multiple sclerosis (MS). Developed at the University of Alberta, dirucotide is being investigated by BioMS Medical Corp. … In particular, the sequence prepared is a 17 amino acid chain that is identical to a section of myelin basic protein (MBP) that is found in humans.

  10. Drug

    Sutimlimab

    go.drugbank.com/drugs/DB14996
    ApprovedInvestigational

    [A245154] Notably, none of these agents are approved for use in the treatment of CAD. … pegcetacoplan], a novel inhibitor of C3.